LOGIN
ID
PW
MemberShip
2025-02-07 04:15
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter's View] Slow but steady wins the race
by
Whang, byung-woo
Feb 4, 2025 05:55am
The Korean government has finally launched the National Bio Commission. The launch of this proper control tower has come several years after the government declared the bio-health industry as a national strategic industry. The news of its launch is encouraging, considering how the launch of the committee itself was almost stranded due to
Opinion
[Reporter's View] Improving rare disease care environment
by
Eo, Yun-Ho
Jan 17, 2025 05:54am
A few patients can only make a small noise. Despite the need for the improvement of the rare disease treatment environment, which has risen year after year, the voice of its patients that implore difficulties has never ceased to exist. In particular, there are cases where a drug is available, but due to the small number of eligible patien
Opinion
[Reporter's View] K-Bio's development and human resource
by
Whang, byung-woo
Jan 14, 2025 05:56am
The Korean pharmaceutical and biotech industry (known as 'K-Bio') has grown robustly over the past few years. K-Bio has successfully out-licensed new drug developments, including the In Vitro Diagnostic (IVD), biosimilar, and CDMO, since the Covid-19 pandemic. However, the industry is concerned about sustainability. The key issue is hu
Opinion
[Reporter¡¯s View] Korean drugs go international this year
by
Son, Hyung Min
Jan 14, 2025 05:56am
Last year, new drugs developed by domestic pharmaceutical companies recorded remarkable achievements overseas. Hanmi Pharmaceutical's Rolontis (U.S. brand name Rolvedon) has continued to grow in the U.S. market. Rolontis is a neutropenia treatment developed by Hanmi Pharmaceutical and became the 33rd new domestic drug to be approved in Ko
Opinion
[Reporter's View] Pharma bio stocks shunned for good reason
by
Kim, Jin-Gu
Jan 8, 2025 05:53am
The sarcastic comment that ¡°escaping from the KOSPI (Korean stock market) is a matter of intelligence¡± has become a trend for some time. Although the so-called ¡°Korea discount¡± is not new, the distrust of the Korean stock market among individual investors has been rising recently. Pharmaceutical, biotech, and healthcare stocks are no
Opinion
[Reporter's View] Switching of drugs reimbursable
by
Eo, Yun-Ho
Jan 6, 2025 05:57am
When a patient chooses one medication and switches to another, reimbursement does not cover the latter. Non-reimbursable drug switching has been a long-standing issue in South Korea. At the end of last year, a long-standing issue in one field was resolved. The Ministry of Health and Welfare (MOHW) granted approval for drug switching for p
Opinion
[Reporter¡¯s View] The dilemma of companion diagnostics
by
Whang, byung-woo
Dec 31, 2024 05:56am
A drug is available but unusable. This is the story of the Claudin 18.2 targeted gastric cancer drug Vyloy (zolbetuximab). This is not the typical situation where a breakthrough drug is approved but is inaccessible due to its high price. The problem is companion diagnostics (CDx). In order to use a Vyloy, which targets Claudin 18.2, i
Opinion
[Desk¡¯s View] No external reference pricing next year?
by
Lee, Tak-Sun
Dec 24, 2024 06:22am
The plan to reevaluate drug prices based on foreign drug prices (external reference pricing), which was expected to be announced by the end of the year, has been delayed. The agenda did not make this year's list at the last Health Insurance Policy Review Committee meeting set for Friday (27th). It is unlikely that the plan will proceed as sc
Opinion
[Reporter¡¯s View] ERP hits industry again
by
Eo, Yun-Ho
Dec 18, 2024 05:55am
Another round of layoffs at multinational pharmaceutical companies are underway with the nearing end of the year. Starting in the second half of the year, 5 companies have already launched early retirement programs (ERPs). The reasons are varied. Whether it's their cash cow crisis, divestitures, or mergers and acquisitions, multinationa
Opinion
[Reporter's view] The National Assembly must restore
by
Lee, Jeong-Hwan
Dec 17, 2024 05:51am
On December 14, the National Assembly passed an impeachment motion against President Yoon Suk Yeol, causing the government to be partially paralyzed. The Ministry of Health and Welfare, the Special Presidential Committee on Healthcare Reform, and the National Bio Committee face significant disruptions in their ongoing policy initiatives.
1
2
3
4
5
6
7
8
9
10
>